JP2004522780A - トルセミド・モディフィケーションｉｉを含む安定な医薬品製剤 - Google Patents

トルセミド・モディフィケーションｉｉを含む安定な医薬品製剤 Download PDF

Info

Publication number
JP2004522780A
JP2004522780A JP2002567302A JP2002567302A JP2004522780A JP 2004522780 A JP2004522780 A JP 2004522780A JP 2002567302 A JP2002567302 A JP 2002567302A JP 2002567302 A JP2002567302 A JP 2002567302A JP 2004522780 A JP2004522780 A JP 2004522780A
Authority
JP
Japan
Prior art keywords
torsemide modification
stable pharmaceutical
pharmaceutical formulation
modification
high purity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002567302A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004522780A5 (enExample
Inventor
レイボビチ，ミヌツァ
テネンガウザー，ルース
コペル，ミラ
アロンヒメ，ジュディス
コルドバ，マルコ
Original Assignee
テバ ファーマシューティカル インダストリーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27359046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2004522780(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by テバ ファーマシューティカル インダストリーズ リミティド filed Critical テバ ファーマシューティカル インダストリーズ リミティド
Publication of JP2004522780A publication Critical patent/JP2004522780A/ja
Publication of JP2004522780A5 publication Critical patent/JP2004522780A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002567302A 2000-02-17 2001-02-21 トルセミド・モディフィケーションｉｉを含む安定な医薬品製剤 Withdrawn JP2004522780A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18328800P 2000-02-17 2000-02-17
PCT/US2001/005577 WO2002067935A1 (en) 2000-02-17 2001-02-21 A stable pharmaceutical formulation comprising torsemide modification ii
US09/789,424 US6482417B2 (en) 2000-02-17 2001-02-21 Stable pharmaceutical formulation comprising torsemide modification II

Publications (2)

Publication Number Publication Date
JP2004522780A true JP2004522780A (ja) 2004-07-29
JP2004522780A5 JP2004522780A5 (enExample) 2006-01-05

Family

ID=27359046

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002567302A Withdrawn JP2004522780A (ja) 2000-02-17 2001-02-21 トルセミド・モディフィケーションｉｉを含む安定な医薬品製剤

Country Status (20)

Country Link
US (1) US6482417B2 (enExample)
EP (1) EP1292303B1 (enExample)
JP (1) JP2004522780A (enExample)
CN (1) CN1505512A (enExample)
AT (1) ATE266404T1 (enExample)
CA (1) CA2410802A1 (enExample)
DE (2) DE1292303T1 (enExample)
DK (1) DK1292303T3 (enExample)
ES (1) ES2193007T3 (enExample)
HR (1) HRP20030762A2 (enExample)
HU (1) HUP0600143A2 (enExample)
IL (1) IL157539A0 (enExample)
IS (1) IS6919A (enExample)
MX (1) MXPA03007908A (enExample)
NO (1) NO20033699L (enExample)
PT (1) PT1292303E (enExample)
SI (1) SI1292303T1 (enExample)
SK (1) SK11632003A3 (enExample)
TR (1) TR200401462T4 (enExample)
WO (1) WO2002067935A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024525954A (ja) * 2021-07-20 2024-07-12 ミネラリス・セラピューティクス・インコーポレイテッド 二置換１，２，４－トリアジン化合物の塩を含む可溶性薬学的組成物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
ITMI20020639A1 (it) * 2002-03-27 2003-09-29 Cosma S P A Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea
WO2005044187A2 (en) * 2003-10-28 2005-05-19 Glaxo Group Limited Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
ES2244324B1 (es) * 2004-03-25 2006-11-16 Ferrer Internacional, S.A. Composiciones diureticas de liberacion prolongada.
CN100421662C (zh) * 2005-11-08 2008-10-01 周卓和 托拉塞米分散片及其制备方法和应用
CN100372534C (zh) * 2006-04-20 2008-03-05 南京海辰药业有限公司 托拉塞米冻干制剂及制备方法
US20080213362A1 (en) * 2007-02-02 2008-09-04 Lawrence Solomon Compositions and methods using torsemide
CN106038500A (zh) * 2016-05-26 2016-10-26 南京正科医药股份有限公司 一种托拉塞米片
GR1010905B (el) * 2024-04-15 2025-03-10 Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, Δισκιο που περιεχει τορασεμιδη

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1477664A (en) 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
DE3529529A1 (de) 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
DE69624559T2 (de) * 1995-02-28 2003-07-10 Aventis Pharmaceuticals Inc., Bridgewater Arzneizubereitungen für piperidinalkanolderivate
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
KR20020025217A (ko) * 1999-08-11 2002-04-03 추후보정 토르세미드 동질이상

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024525954A (ja) * 2021-07-20 2024-07-12 ミネラリス・セラピューティクス・インコーポレイテッド 二置換１，２，４－トリアジン化合物の塩を含む可溶性薬学的組成物

Also Published As

Publication number Publication date
MXPA03007908A (es) 2004-12-06
SK11632003A3 (sk) 2004-04-06
DE1292303T1 (de) 2003-09-18
NO20033699D0 (no) 2003-08-20
PT1292303E (pt) 2004-09-30
IS6919A (is) 2003-08-20
IL157539A0 (en) 2004-03-28
ES2193007T1 (es) 2003-11-01
CA2410802A1 (en) 2002-09-06
HRP20030762A2 (en) 2005-08-31
WO2002067935A1 (en) 2002-09-06
SI1292303T1 (en) 2004-10-31
HUP0600143A2 (en) 2006-10-28
ATE266404T1 (de) 2004-05-15
US20020035135A1 (en) 2002-03-21
EP1292303A1 (en) 2003-03-19
DE60103276T2 (de) 2005-06-23
NO20033699L (no) 2003-10-10
EP1292303A4 (en) 2003-07-09
DK1292303T3 (da) 2004-09-06
DE60103276D1 (de) 2004-06-17
US6482417B2 (en) 2002-11-19
CN1505512A (zh) 2004-06-16
ES2193007T3 (es) 2004-11-01
EP1292303B1 (en) 2004-05-12
TR200401462T4 (tr) 2004-08-23

Similar Documents

Publication Publication Date Title
JP2004528345A (ja) Ａｃｅ／ｎｅｐインヒビターおよびバイオアベイラビリティーエンハンサーを含む薬学的組成物
TWI848241B (zh) １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶之製備方法及包含彼之醫藥組成物
JP2002529407A (ja) Ｌ−ｄｏｐａエチルエステル含有分散性組成物
JP3518601B2 (ja) エバスタイムまたはその類似体に基づく医薬組成物
JP2001513801A (ja) パラセタモールを含む嚥下錠剤
US6482417B2 (en) Stable pharmaceutical formulation comprising torsemide modification II
JP7428356B2 (ja) 高いバイオアベイラビリティを有するソラフェニブの医薬組成物、ソラフェニブ経口固形製剤、及びその使用
FI89455C (fi) Foerfarande foer framstaellning av en farmaceutisk komposition
US20030022921A1 (en) Stable pharmaceutical formulation comprising torsemide modification II
JPH0737383B2 (ja) 胃酸分泌抑制剤含有固型製剤
KR20090013736A (ko) 메트포르민 산 부가염을 포함하는 서방성 제제
AU2001238617A1 (en) A stable pharmaceutical formulation comprising torsemide modification II
TWI901422B (zh) 一種嘧啶類衍生物的藥物組合物
CN104744404A (zh) 稳定的氢氯噻嗪晶体化合物、其复方马来酸依那普利药物组合物
ZA200306679B (en) A stable pharmaceutical formulation comprising torsemide modification II.
CN102666528A (zh) 晶体cdc7 抑制剂盐
CZ20032513A3 (cs) Stabilní farmaceutický přípravek obsahující modifikaci II torsemidu
CN119060046A (zh) 含有格拉匹纶盐酸盐的药物制剂及其制备方法
KR20030077638A (ko) 토르세마이드 변형체 ⅱ를 포함하는 안정한 약학 제제
KR910004481B1 (ko) 용출성이 개량된 제제 조성물
CN106032364A (zh) 新利司他晶体
CN105581988A (zh) 一种缬沙坦的口腔崩解片
JPH023609A (ja) 塩酸ニカルジピンを活性成分とする持効性製剤
BG62228B2 (bg) Безводна кристална натриева сол на 5-хлор-3-(2-теноил)-2- оксиндол-1-карбоксамид

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040825

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20070312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070312